Effects of the Chunghyuldan on the Prevention of Ischemic Stroke Recurrence
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0008052
- Lead Sponsor
- Kyung Hee University Oriental Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Among patients who visited the Department of cardiology and neurology at Kyunghee University Korean Medicine Hospital from January 1, 2017 to December 31, 2020, those who met the following conditions:
• Patients aged 19 years or older who were diagnosed with cerebral infarction (I63) by combining brain imaging tests (Brain CT or MR) and clinical symptoms
• A person who has been prescribed and taken Chunghyuldan (hospital code: DHH333) for more than 30 days to prevent recurrence of ischemic stroke
• A person who has been observed for more than 2 years after starting to take Chunghyuldan
• A person who has administered antiplatelet agents and anticoagulants in combination
• A person who has undergone follow-up for more than 2 years but has insufficient medical records to determine whether there is a recurrence of cerebral infarction.
• In the case principal investigators and sub-investigators judge that they are not appropriate for research and analysis
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence of ischemic stroke
- Secondary Outcome Measures
Name Time Method Patients' demographic data, Concomitant diseases, social history, Use of combined antiplatelet therapy,TOAST determined, period of Chunghyuldan administration, adverse effect